Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • CD147+ Extracellular Vesicles Drive Angiogenesis via PI3K/Ak

    2026-05-01

    CD147-Positive Small Extracellular Vesicles Orchestrate Angiogenesis in Hepatocellular Carcinoma via PI3K/Akt Signaling

    Study Background and Research Question

    Hepatocellular carcinoma (HCC) remains the most prevalent primary liver malignancy worldwide and is a leading cause of cancer-related death. Tumor angiogenesis, the process by which new blood vessels are formed, is essential for HCC progression, facilitating both tumor growth and metastatic spread. However, the current diagnostic tools—such as alpha-fetoprotein (AFP) measurement and imaging—often lack sensitivity and specificity, particularly for early-stage or atypical cases. Recent research has shifted focus toward the diagnostic and mechanistic significance of circulating small extracellular vesicles (sEVs), which can shuttle oncogenic proteins and signaling molecules between cells. In this context, Huang et al. set out to identify sEV-associated molecules that not only serve as diagnostic biomarkers, but also actively regulate angiogenesis in HCC (Huang et al., 2023).

    Key Innovation from the Reference Study

    A major innovation of this study is the identification of CD147, a transmembrane glycoprotein, as a significantly enriched component of HCC-derived sEVs. The authors demonstrate that CD147-positive sEVs (CD147+ sEVs) are not merely passive biomarkers, but active participants in the tumor microenvironment, directly promoting angiogenesis in endothelial cells. This dual role—diagnostic and mechanistic—distinguishes CD147+ sEVs from previously characterized vesicular biomarkers in liver cancer (Huang et al., 2023).

    Methods and Experimental Design Insights

    The research team employed a multifaceted approach encompassing clinical sample analysis, in vitro functional assays, and in vivo validation. Key methodological highlights include:
    • Clinical sEV Profiling: Plasma samples from 155 HCC patients, 59 liver cirrhosis (LC) patients, and 82 healthy donors (HD) were analyzed using nano-flow cytometry (nFCM) to quantify CD147+ sEVs. This enabled robust comparison of sEV populations across disease states.
    • Cellular and Molecular Assays: Endothelial cell responses to HCC-derived CD147+ sEVs were interrogated via proliferation, scratch wound healing, transwell migration/invasion, and tube formation assays, providing quantitative and qualitative insights into angiogenic activation.
    • Mechanistic Analysis: Levels of vascular endothelial growth factor A (VEGFA) and markers of PI3K/Akt pathway activation were measured following sEV treatment. Pharmacological inhibition and RNA interference experiments further dissected pathway dependencies.
    • In Vivo Validation: The angiogenic potential of sEVs was confirmed using a Matrigel plug assay in mice, lending translational relevance to the in vitro findings.

    Protocol Parameters

    • nano-flow cytometry (nFCM) | 155 HCC, 59 LC, 82 HD samples | Diagnostic biomarker quantitation | Enables high-throughput sEV profiling and comparison across cohorts | paper
    • Scratch wound healing assay | 24 h endpoint | Endothelial cell migration | Measures sEV-induced pro-migratory effects on HUVECs | paper
    • Tube formation assay | 6 h endpoint | Angiogenesis modeling | Quantifies capillary network formation in vitro upon sEV exposure | paper
    • PI3K/Akt inhibition (pharmacological) | Not numerically specified | Pathway dependency assessment | Confirms CD147+ sEV action via PI3K/Akt signaling | paper
    • MK-2206 dihydrochloride (typical in vitro use) | 1–2 μM | PI3K/Akt pathway inhibition | Selective allosteric Akt1/2/3 inhibition, suitable for apoptosis and pathway assays | workflow_recommendation

    Core Findings and Why They Matter

    Huang et al. report several pivotal findings:
    • Diagnostic Elevation: Plasma CD147+ sEVs are significantly elevated in HCC patients compared to both LC patients and healthy controls. This suggests high potential for non-invasive diagnosis (Huang et al., 2023).
    • Functional Angiogenesis Driver: HCC cell-derived CD147+ sEVs enhance proliferation, migration, invasion, and tube formation of endothelial cells, demonstrating their active role in promoting angiogenesis (Huang et al., 2023).
    • Mechanistic Pathway: These effects are mediated by the upregulation of VEGFA and activation of the PI3K/Akt signaling pathway within recipient endothelial cells. Inhibiting this pathway abrogates the pro-angiogenic effects of CD147+ sEVs (Huang et al., 2023).
    • In Vivo Confirmation: The angiogenesis-promoting capacity of these vesicles is recapitulated in the Matrigel plug mouse model, underscoring the translational relevance.
    These integrated results provide compelling evidence for CD147+ sEVs as both a diagnostic marker and a functional therapeutic target in HCC, particularly within the context of PI3K/Akt pathway regulation.

    Comparison with Existing Internal Articles

    The PI3K/Akt/mTOR axis is a well-established target in oncology and metabolic research. The current findings align with and extend insights discussed in several internal articles: These connections illustrate how the present study’s findings can inform and be enhanced by established research tools and protocols for pathway interrogation and functional readouts.

    Limitations and Transferability

    Despite its strengths, the study has several limitations:
    • Patient Cohort Diversity: The patient samples were drawn from a single center, and while the numbers are robust, multi-center validation would strengthen generalizability.
    • Quantitative Thresholds: While CD147+ sEVs show promise as a biomarker, specific cutoff values for clinical diagnosis require further prospective validation.
    • Therapeutic Translation: Although pathway inhibition abrogates angiogenesis in vitro, in vivo therapeutic studies targeting CD147+ sEVs or the PI3K/Akt pathway in HCC models are needed to confirm efficacy and safety.
    • Cross-domain Considerations: The mechanistic paradigm is highly relevant for other angiogenesis-driven malignancies, but direct evidence in non-HCC contexts remains to be established (Huang et al., 2023).

    Why this cross-domain matters, maturity, and limitations

    While the PI3K/Akt pathway is broadly implicated in tumor angiogenesis, the explicit link between CD147+ sEVs and vascular activation has so far been demonstrated only in HCC. Extensions to other cancer types or vascular pathologies should be interpreted with caution until validated in those contexts (Huang et al., 2023).

    Research Support Resources

    For researchers aiming to further dissect the PI3K/Akt signaling pathway in angiogenesis or apoptosis assays, MK-2206 dihydrochloride (SKU A3010) is a well-characterized, selective allosteric inhibitor of Akt1/2/3. Its established use in functional and mechanistic studies—including apoptosis induction and pathway inhibition—is supported by recent workflow recommendations and internal literature (internal_article). Proper solubilization and storage protocols, as described by APExBIO, help ensure reproducible results in both cancer and vascular research contexts (source: product_spec).